Projects

Funding stream: EU4Health

Duration: 18 months (2022-2023)

Partners: ECO, OECI, ESSO, SIOG, EFIC, ESP, Tartu University Hospital, ESGO, EUSOMA, ESTRO, EASL, University of Cyprus, Institut Curie, ESSM, APSCO, Heidelberg University, University Politecnica de Valencia, Trinity College Dublin, EONS, EATEL, EAPC, ESO, Champalimaud Foundation, ESPEN, University of Ljubljana, NCI, EASO, EANM, University College Dublin, ELF, Medical University of Gdansk, EAU 

EANM’s role: Consortium Member 

Scope and objectives:

• As part of the Europe’s Beating Cancer Plan, INTERACT-EUROPE has brought together 33 partners from 17 countries aiming at developing a European inter-specialty cancer training programme involving all main oncology disciplines and professions, cancer centres and patient groups, based on relevant needs assessments.
• The project has fostered a patient-centric approach to quality cancer care through the promotion of multi-disciplinary and multi-professional team working.

Main deliverables: 

• INTERACT-EUROPE’s blueprint for high functioning multidisciplinary cancer care in every country
• INTERACT-EUROPE’s European Inter-specialty Cancer Training Programme Curriculum

Website

Funding stream: EU4Health

Duration: 36 months (2023-2026)

Partners: 38 partners including ECO, Heidelberg University, ESSO, Wien Medical University, ESTRO, ESO, Graz Medical University, EANM, Health Assessment Europe, EAPC, ESP, EONS, Complex Oncology Centre, Institut Curie, ESOP, SIOPE, Wonca etc.

EANM’s role: Consortium member 

Scope & objectives: As the second phase of the EU co-funded project for an Inter-Specialty Cancer Training Programme (ISCTP), INTERACT-EUROPE 100 is an ambitious project to provide cancer care professionals with the training necessary to enhance multidisciplinary collaboration – now bringing the ISCTP to 100 cancer centres across Europe, building on the work of INTERACT-EUROPE.

Interested Cancer Centres: visit the INTERACT-EUROPE website to sign up

Website

Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

Funding stream: ERASMUS+

Duration: 24 months (2022-2024)

Partners: KU Leuven, Policlinico Gemelli, I.R.S.T. Meldola, European Association of Urology, University of Duisburg-Essen, Eberhard Karl, University of Tübingen, Centre Léon Bérard, Hospital Sant Pau, Semmelweis University, Andcode, EANM

EANM’s role: Consortium Member (Work Package 2 Lead)

Scope & objectives:

• The RLT Academy project aims to launch a multidisciplinary and transnational blended education programme for healthcare professionals on the use of radioligand therapies in cancer care.
• The RLT Academy project will launch specialised training programmes on radioligand therapies for healthcare professionals in Europe and globally.
• The project will contribute to greater adoption of RLTs across Europe (and the world) by closing the capacity gap and allowing healthcare professionals to establish and expand RLT services.

Main deliverables:

• Radioligand therapies in cancer: mapping the educational landscape in Europe
• Radioligand Therapy – Basic Course

Website

Funding stream: EU4Health

Duration: 36 months (2024-2027)

Partners: EIBIR (Project Coordinator), EANM, University Hospital Schleswig-Holstein (Scientific Coordinator), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, HUMANITAS Mirasole SPA (Scientific Coordinator), Clinical Hospital Dubrava, Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, German Oncology Center Cyprus, Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, University Multipurpose Hospital for Active Treatment “Sveti Georgi”, University Medical Centre Ljubljana, University of Crete, University Hospital Essen.

Affiliated entities: Hospital Clinic Barcelona

EANM’s role: Consortium Member (Work Package 4 Co-Lead)

The CLAUD-IT project is set to elevate patient care across Europe by supporting EU Member States in implementation of clinical audit, with a focus on radiology and nuclear medicine. CLAUD-IT connects hospitals, authorities, and societies in 9 EU Member States to develop clinical audit guidelines, methodology, and supporting documents. This initiative will train over 250 professionals, empowering them to lead audits and improve healthcare quality and safety across EU.

Scope & objectives:

• Assess the current state of the art in all 9 participating Member States to identify new developments since the completion of the QuADRANT project as well as existing infrastructures and stakeholders.
• Prepare practical, concise and evidence-based audit material and related training material for radiology and nuclear medicine and to make these available in a central repository in order to provide a “one-stop-shop” for stakeholders.
• Hold practical stakeholder training to conduct clinical audits under external guidance.
• Raise awareness for the importance of clinical audit by communicating its mandatory character as laid down in the BSSD and explaining the great impact it can have on daily professional practice as well as its contribution to higher quality care and patient safety. Convene the stakeholders in an effort to develop clinical audit strategies and campaigns.

Funding stream: HORIZON

Duration: 2024-2029

Partners: UK Essen, Policlinico Universitario Fondazione Agostino Gemelli Roma, EANM, Collaborate, GE Healthcare, Institut Jules Bordet, Oncidium, Hospital General Universitario Gregorio Marañón, Erasmus MC, ICO, SCK CEN, Datawizard, Curasight, Minerva Imaging, Exini, Aiforia, Atley Solutions, DOSIsoft, Terthera.

EANM’s role: Consortium Member

Scope & objectives:

• Strengthen manufacturing and supply chains for radiotheranostics.
• Optimise timely, cost-effective delivery to healthcare facilities.
• Develop lab-based cancer models for testing theranostics before human trials.
• Support testing and market access of innovative theranostic solutions.
• Create a flexible, adaptive framework for phase 1 radiopharmaceutical trials.
• Enable trials to adjust to interim results and new treatments.
• Advance AI-based imaging techniques.
• Develop personalised dosing protocols to improve patient outcomes.
• Establish a multi-modal oncology platform for visualising relevant patient data.
• Establish an EU network of radiotheranostics centres to rapidly develop and implement tools and solutions for precision health.

Website